1. Survival Effect of Surgery in Patients with Stage IIIB/N2 Non-small Cell Lung Cancer: A Comparative Study with Definitive Chemoradiotherapy.
- Author
-
Erdoğu, Volkan, Aksoy, Yunus, Sezen, Celal Buğra, Doğru, Mustafa Vedat, Yıldız, Nisa, Cansever, Levent, and Metin, Muzaffer
- Subjects
- *
LUNG cancer , *NONPARAMETRIC statistics , *CONFIDENCE intervals , *LOG-rank test , *RETROSPECTIVE studies , *POSITRON emission tomography computed tomography , *FISHER exact test , *MANN Whitney U Test , *CHEMORADIOTHERAPY , *TREATMENT effectiveness , *TUMOR classification , *COMPARATIVE studies , *CANCER patients , *T-test (Statistics) , *QUALITATIVE research , *PEARSON correlation (Statistics) , *SURVIVAL analysis (Biometry) , *DESCRIPTIVE statistics , *CHI-squared test , *KAPLAN-Meier estimator , *COMBINED modality therapy , *DATA analysis software , *OVERALL survival - Abstract
OBJECTIVE: We compared the survival outcomes of surgery within multimodality treatment regimens with the outcomes of definitive chemoradiation treatments in patients diagnosed with clinical (c) IIIB/N2 non-small cell lung cancer (NSCLC). We investigated whether surgery within multimodality treatment provides a survival advantage at this stage. MATERIAL AND METHODS: Data from 79 patients with cIIIB/N2 between 2009 and 2016 were analyzed retrospectively. While the surgery was performed after neoadjuvant therapy in 51 cases (IIIB/Surgery Group), definitive chemotherapy ± radiotherapy was applied in 28 cases (IIIB/Definitive Group). RESULTS: In cIIIB/N2 cases, the 5-year overall survival (OS) was 27.4%, with a median OS of 24.6 months. The 5-year OS of the IIIB/ Surgery Group was 27.3% (median survival 22.5 months), while it was 28.6% (median survival 29.1 months) in the IIIB/Definitive Group (P = .387, HR = 0.798, 95% CI, 0.485-1.313). Although there was a survival advantage in the group with a pathological complete response (PCR) after surgery (n = 14) compared to the group that did not (n = 37), the observed difference was not statistically significant. (5-year OS; 42.9% vs. 18.5%, P = .104). Additionally, there was no statistically significant difference between the survival of PCR patients and the IIIB/Definitive Group in terms of OS (P = .488). CONCLUSION: Surgery performed within multimodality treatment regimens in selected cIIIB/N2 cases did not provide a survival advantage over definitive chemoradiation treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF